FDA approves subcutaneous opdivo qvantig for most solid tumor indications

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications.

Leave A Comment

Your email address will not be published. Required fields are marked *